Results 21 to 30 of about 54,096 (328)

Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome

Cancer, 2023
Patients with cytopenic myelofibrosis (MF) have more limited therapeutic options and poorer prognoses compared with patients with the myeloproliferative phenotype.
F. Palandri, M. Breccia, C. Mazzoni, G. Auteri, E. Elli, M. Trawinska, N. Polverelli, M. Tiribelli, G. Benevolo, A. Iurlo, A. Tieghi, F. Heidel, G. Caocci, E. Beggiato, G. Binotto, F. Cavazzini, M. Miglino, C. Bosi, M. Crugnola, M. Bocchia, B. Martino, N. Pugliese, Mattia Biondo, M. Venturi, L. Scaffidi, A. Isidori, D. Cattaneo, M. Krampera, F. Pane, D. Cilloni, G. Semenzato, R. Lemoli, A. Cuneo, E. Abruzzese, D. Bartoletti, Simona Paglia, N. Vianelli, M. Cavo, M. Bonifacio, G. Palumbo   +39 more
semanticscholar   +1 more source

Pediatric immune myelofibrosis (PedIMF) as a novel and distinct clinical pathological entity

Frontiers in Pediatrics, 2022
Myelofibrosis is a rare myeloproliferative disorder. The detailed descriptions of myelofibrosis in children and adolescents is limited to a few case series and case reports describing fewer than 100 patients, thus suggesting the extreme rarity of this ...
Fabiola Guerra, Fabiola Guerra, Vincenzo L’Imperio, Sonia Bonanomi, Marco Spinelli, Tiziana Angela Coliva, Fabiola Dell’Acqua, Giulia Maria Ferrari, Paola Corti, Adriana Balduzzi, Andrea Biondi, Fabio Pagni, Francesco Saettini   +12 more
doaj   +1 more source

Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy

Journal of Clinical Oncology, 2022
PURPOSE Targeting the BCL-XL pathway has demonstrated the ability to overcome Janus kinase inhibitor resistance in preclinical models. This phase II trial investigated the efficacy and safety of adding BCL-XL/BCL-2 inhibitor navitoclax to ruxolitinib ...
C. Harrison, Jacqueline S. Garcia, T. Somervaille, J. Foran, S. Verstovsek, C. Jamieson, R. Mesa, E. Ritchie, S. Tantravahi, P. Vachhani, C. O'Connell, R. Komrokji, Jason G. Harb, Jessica E. Hutti, Leanne Holes, A. Masud, Silpa Nuthalapati, J. Potluri, N. Pemmaraju   +18 more
semanticscholar   +1 more source

Momelotinib: an emerging treatment for myelofibrosis patients with anemia

Journal of Hematology & Oncology, 2022
The suite of marked anemia benefits that momelotinib has consistently conferred on myelofibrosis (MF) patients stem from its unique inhibitory activity on the BMP6/ACVR1/SMAD and IL-6/JAK/STAT3 pathways, resulting in decreased hepcidin (master iron ...
H. Chifotides, P. Bose, S. Verstovsek
semanticscholar   +1 more source

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis

Blood Advances, 2022
Key Points • Pacritinib exhibits fourfold higher potency for inhibition of the hepcidin regulator ACVR1 compared to momelotinib based on in vitro data.• Pacritinib is associated with an increase in red blood cell transfusion independence in patients with
S. Oh, Ruben A. Mesa, C. Harrison, P. Bose, A. Gerds, M. Heaney, V MNSSVKR GUPTA, B. Scott, J. Kiladjian, A. Lucchesi, S. Buckley, Shanthakumar R. Tyavanagimatt, K. Roman‐Torres, J. Mascarenhas, S. Verstovsek   +14 more
semanticscholar   +1 more source

A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis

Blood Advances, 2022
Key Points RUX dose, spleen response, and transfusion requirement in the first 6 months of RUX treatment predict overall survival in MF. The RR6 model overcomes conventional risk stratification in RUX-treated MF.
M. Maffioli, B. Mora, S. Ball, A. Iurlo, E. Elli, M. Finazzi, N. Polverelli, E. Rumi, M. Caramella, M. Carraro, M. D'adda, A. Molteni, C. Sissa, F. Lunghi, A. Vismara, M. Ubezio, A. Guidetti, S. Caberlon, M. Anghilieri, R. Komrokji, D. Cattaneo, M. D. Della Porta, T. Giorgino, L. Bertù, M. Brociner, A. Kuykendall, F. Passamonti   +26 more
semanticscholar   +1 more source

VEGFA rs3025020 Polymorphism Contributes to CALR-Mutation Susceptibility and Is Associated with Low Risk of Deep Vein Thrombosis in Primary Myelofibrosis

TH Open, 2021
Background Single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor A (VEGFA) are associated with susceptibility to several diseases including cancer.
Laura Villani, Vittorio Rosti, Margherita Massa, Rita Campanelli, Paolo Catarsi, Adriana Carolei, Carlotta Abbà, Annalisa de Silvstri, Robert Peter Gale, Giovanni Barosi   +9 more
doaj   +1 more source

AIF1+CSF1R+ MSCs, induced by TNF‐α, act to generate an inflammatory microenvironment and promote hepatocarcinogenesis

Hepatology, EarlyView., 2022
Mesenchymal stem cells subset, educated by TNF‐α, are involved to generate inflammatory microenvironment and promote hepatocarcinogenesis Abstract Background and Aims Increasing evidence suggests that mesenchymal stem cells (MSCs) home to injured local tissues and the tumor microenvironment in the liver.
Chen Zong, Yan Meng, Fei Ye, Xue Yang, Rong Li, Jinghua Jiang, Qiudong Zhao, Lu Gao, Zhipeng Han, Lixin Wei   +9 more
wiley   +1 more source

Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm

Nature Communications, 2022
Interleukin-1β (IL-1β) is a master regulator of inflammation. Increased activity of IL-1β has been implicated in various pathological conditions including myeloproliferative neoplasms (MPNs).
S. Rai, Élodie Grockowiak, N. Hansen, Damien Luque Paz, Cédric B. Stoll, Hao Hui, Gabriele Mild-Schneider, S. Dirnhofer, C. Farady, S. Méndez-Ferrer, R. Skoda   +10 more
semanticscholar   +1 more source

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

Hepatology, EarlyView., 2022
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres, Cristina Ortiz, Nadine Bachtler, Wenyi Gu, Leon D. Grünewald, Nico Kraus, Robert Schierwagen, Christoph Hieber, Caroline Meier, Olaf Tyc, Maximilian Joseph Brol, Frank Erhard Uschner, Bart Nijmeijer, Christoph Welsch, Marie‐Luise Berres, Carmen Garcia‐Ruiz, Jose Carlos Fernandez‐Checa, Christian Trautwein, Thomas J. Vogl, Stefan Zeuzem, Jonel Trebicka, Sabine Klein   +21 more
wiley   +1 more source